USRE42718EExpiredUtility

Crude extracts from andrographis paniculata

80
Assignee: HUTCHISON MEDIPHARMA ENTPR LTDPriority: Apr 28, 2004Filed: Mar 4, 2010Granted: Sep 20, 2011
Est. expiryApr 28, 2024(expired)· nominal 20-yr term from priority
A61P 37/04A61P 9/04A61P 3/10A61P 37/06A61P 37/02A61P 35/02A61P 29/00A61P 27/02A61P 31/04A61P 31/18A61P 25/28A61P 1/04A61P 11/06A61P 1/02A61P 21/00A61P 1/18A61P 17/00A61P 17/06A61P 1/00A61K 36/19A61K 31/365
80
PatentIndex Score
4
Cited by
152
References
13
Claims

Abstract

This invention relates to a method of inhibiting TNFα or IL-1β expression with an extract of Andrographis paniculata. The extract contains andrographolide, 14-deoxy-andrographolide, 14-deoxy-11,12-dehydrogen-andrographolide, and neoandrographolide.

Claims

exact text as granted — not AI-modified
1. A method of treating an inflammatory bowel disease in a subject in recognized need thereof, comprising administering to the subject an effective amount of an extract of Andrographispaniculata, wherein the extract contains 2-20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1-12 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide. 
     
     
       2. The method of  claim 1 , wherein the extract contains 3-8% by weight andrographolide, 3 1-5% by weight 14-deoxy-andrographolide, 1.0-7-9% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide. 
     
     
       3. The method of  claim 2 , wherein the extract contains 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrograpliolide, 8% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide. 
     
     
       4. The method of  claim 1 , wherein the inflammatory bowel disease is Crohn's disease. 
     
     
       5. The method of  claim 1 , wherein the inflammatory bowel disease is ulcerative colitis. 
     
     
       6. The method of  claim 5 , wherein the extract contains 3-8% by weight andrographolide, 3 1-5% by weight 14-deoxy-andrographolide, 1.0-7-9% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide. 
     
     
       7. The method of  claim 6 , wherein the extract contains 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrographolide, 8% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide. 
     
     
       8. A method of treating an inflammatory bowel disease comprising administering to a patient in recognized need of such treatment an effective amount for treating of an extract of Andrographis paniculata, comprising: 2-20% by weight andrographolide, 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide. 
     
     
       9. A method of treating an inflammatory bowel disease comprising administering to a patient in recognized need of such treatment an effective amount for treating of an extract of Andrographis paniculata, comprising 2-20% by weight andrographolide, 14-deoxy-andrographolide, 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide. 
     
     
       10. The method of claim 8 wherein said inflammatory bowel disease is Crohn's disease. 
     
     
       11. The method of claim 8 wherein said inflammatory bowel disease is ulcerative colitis. 
     
     
       12. The method of claim 9 wherein said inflammatory bowel disease is Crohn's disease. 
     
     
       13. The method of claim 9 wherein said inflammatory bowel disease is ulcerative colitis.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.